Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some ...

After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...

Gilead Sciences (GILD) ended the recent trading session at $85.83, demonstrating a +0.91% swing from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 0.76%.

In the latest market close, Gilead Sciences (GILD) reached $85.21, with a +0.92% movement compared to the previous day. The stock's performance was behind the S&P 500's daily gain of 0.97%.

Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target ...

Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A new study suggests Leqembi's vial design could cost Medicare hundreds of millions of dollars in waste each year.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform ...

In this piece, we will look at where Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the list of stocks that mutual funds are buying according to Goldman Sachs. As the fourth quarter of 2024 ...